Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris

Launched by CHANG GUNG MEMORIAL HOSPITAL · Oct 27, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a medication called topical minoxidil for treating acne vulgaris, which is a common skin condition that causes pimples. The trial is currently looking for participants aged 20 to 50 who have mild to moderate acne. To be eligible, individuals must not be pregnant or breastfeeding, must not have any allergies to minoxidil, and should have stopped any other acne treatments for a specified period before joining the study.

Participants in this trial can expect to have some tests done at the beginning to check their blood and urine, along with daily photos taken of their acne. Over the course of the trial, researchers will monitor the number of acne lesions, how quickly they improve, and assess the overall severity of the acne. This study aims to understand how safe minoxidil is for acne treatment and how well it works, helping to find better options for those suffering from acne.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Gender: both
• • 2. Age limit: 20\~50 year/old
• • 3. Acne vulgaris: mild to moderate degree (Investigator's Global Assessment Scale:2\~3)
• Exclusion Criteria:
• • 1. pregnant or breast feeding woman
• • 2. allergic to minoxidil or any ingredient of minoxidil solution including alcohol and propylene glycol
• • 3. deny to discontinue topical therapy of acne more than 7 days before starting treatment
• • 4. deny to discontinue systemic therapy of acne more than 28 days before starting treatment
• • 5. alopecia under or ever using minoxidil, known androgen-AR pathway blocker
• • 6. using shampoo containing minoxidil component in 28 days before starting treatment
• • 7. irregular menstruation of known case of polycystic ovarian syndrome
• • 8. Have had a facial procedure 2 weeks before the study start
• • 9. using any oral contraceptives that have a specific anti-androgenic action 12 weeks before the study start